Traders should monitor upcoming data readouts from the trial, particularly preliminary efficacy signals, which could serve as a major catalyst. The successful enrollment and completion across multiple sites reduce execution risk and support potential for future financing or partnerships.
Price Chart
Executive Summary
Clearmind Medicine announced the successful completion of treatment and follow-up for 18 participants in its ongoing Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder, with an additional four participants treated at its Tel Aviv site. This progress highlights continued momentum in the multinational trial evaluating the safety, tolerability, and preliminary efficacy of its lead drug candidate.
Key Facts
- 18 participants have completed treatment and follow-up in the Phase I/IIa trial of CMND-100 for Alcohol Use Disorder.
- Four additional participants were successfully treated at the Tel Aviv clinical site.
- The trial is multinational and multicenter, including sites at Yale University, Johns Hopkins, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
- CMND-100 is a non-hallucinogenic, oral drug candidate based on MEAI, targeting moderate to severe AUD.
- The company emphasized the favorable safety and tolerability profile observed thus far.
Financial Impact
No direct financial impact reported; trial progress may enhance valuation potential and investor interest.
Risk Factors
- Clinical trial results may not meet efficacy endpoints despite positive safety signals.
- As a micro-cap biotech (market cap $1M), the stock is highly speculative and sensitive to binary outcomes.
- Forward-looking statements carry inherent uncertainty; actual results may differ materially.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-036044 |
| Document: ea028400202ex99-1.htm | 0001213900-26-036044 |
| Document: 0001213900-26-036044-index-headers.html | 0001213900-26-036044 |
| Document: 0001213900-26-036044-index.html | 0001213900-26-036044 |
| Document: 0001213900-26-036044.txt | 0001213900-26-036044 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | — | awaiting T+60 | — | — |
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.97 (+0.79%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.97 (−8.20%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $5.97 (+0.55%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.97 (−4.22%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.97 (+602.00%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.97 (+602.00%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.97 (−13.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers